文献速递临床试验与 GCP基础与转化研究

干预性维生素复合青光眼研究(IVMGS):在现有青光眼患者中开展的前瞻性、随机、两臂、单中心试验的研究方案

Interventional Vitamin Mix Glaucoma Study (IVMGS): study protocol for a prospective, randomized, two-arm, single-center trial in existing glaucoma patients.
PubMed 文献 · Trials · 2025-10-13

IVMGS是一项2a期、开放标签、随机、两臂、单中心临床试验,计划于2025年3月至2026年3月在瑞典斯德哥尔摩招募80例原发性开角型青光眼、正常眼压性青光眼或假性剥脱性青光眼且至少一眼轻中度视野缺损的患者,1:1分配接受每日一碳代谢补充剂(维生素B6、B9、B12和胆碱)联合标准治疗或单纯标准治疗,主要结局为全视野视网膜电图明视负波反应变化。

要点

  • 2a期开放标签随机两臂试验,评估一碳代谢补充联合标准治疗对青光眼视网膜功能的影响。
  • 计划纳入80例原发性开角型、正常眼压性或假性剥脱性青光眼且至少一眼轻中度视野缺损患者。
  • 主要结局为全视野视网膜电图明视负波反应变化,探索性结局包括血液代谢组和DNA甲基化谱变化。

核心结论

  • 该试验将研究一碳代谢补充剂是否能改善青光眼患者的视网膜功能并提供神经保护。
  • 若研究成功,该方法可能支持一种低成本、广泛可用的神经保护策略,与现有降眼压治疗联合使用。

研究设计与样本

  • 2a期、开放标签、随机、两臂、单中心临床试验,参与者按1:1比例分配。
  • 计划入组80例原发性开角型青光眼、正常眼压性青光眼或假性剥脱性青光眼患者,每例至少一眼存在轻中度视野缺损。
  • 招募时间为2025年3月至2026年3月,地点为瑞典斯德哥尔摩卡罗林斯卡学院圣埃里克眼科医院。

主要发现

  • 该研究方案尚未报告结果数据。
  • 研究组既往在啮齿动物模型中的临床前研究发现一碳代谢功能障碍与青光眼性神经变性有关。

关键数值与推荐

  • 主要结局为全视野视网膜电图测量的明视负波反应变化。
  • 次要结局包括视野参数、视网膜神经纤维层厚度和神经节细胞-内丛状层厚度变化。
  • 探索性结局包括血液代谢组学和DNA甲基化谱变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glaucoma is a leading cause of irreversible blindness, characterized by progressive degeneration of retinal ganglion cells. Current treatments primarily lower intraocular pressure but do not directly provide neuroprotection. Preclinical studies from our group have identified dysfunction in one-carbon metabolism as a contributor to glaucomatous neurodegeneration in rodent models. The Interventional Vitamin Mix Glaucoma Study will evaluate whether 12 months of supplementation with key one-carbon metabolism cofactors and precursors (vitamins B6, B9, B12, and choline) can improve inner retinal function and provide neuroprotection compared with standard care alone. METHODS: The Interventional Vitamin Mix Glaucoma Study is a Phase 2a, open-label, randomized, two-arm clinical trial. Participants will be assigned in a one-to-one ratio to receive either daily one-carbon metabolism supplementation plus standard care or standard care alone. The study will enroll 80 patients with primary open-angle glaucoma, normal tension glaucoma, or pseudoexfoliation glaucoma, each with mild-to-moderate visual field loss in at least one eye. Recruitment will take place from March 2025 to March 2026 at St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden. The primary outcome is change in the photopic negative response measured by full-field electroretinography. Secondary outcomes include changes in visual field parameters, retinal nerve fiber layer thickness, and ganglion cell-inner plexiform layer thickness. Exploratory outcomes will include changes in blood-based metabolomic and DNA methylation profiles. DISCUSSION: One-carbon metabolism-based supplementation has been shown to reduce retinal ganglion cell loss in rodent models of glaucoma. This trial will investigate whether such supplementation improves retinal function and confers neuroprotection in patients with glaucoma. The use of full-field electroretinography as the primary outcome aims to detect early functional improvements in the retina. If successful, this approach could support a low-cost, widely available neuroprotective strategy to be used alongside existing intraocular pressure-lowering therapies. TRIAL REGISTRATION: This trial is registered at ClinicalTrials.gov (NCT06885827), first posted on 20 March 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Golpour N, Hui F, Nilsson M, et al. Interventional Vitamin Mix Glaucoma Study (IVMGS): study protocol for a prospective, randomized, two-arm, single-center trial in existing glaucoma patients. Trials. 2025. PMID: 41084053. doi:10.1186/s13063-025-09168-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。